SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

United States Commodity Funds LLC - United States Oil Fund

United States Oil Fund

The United States Oil Fund is trending due to rapidly escalating geopolitical tensions in the Middle East following reports of U.S.-Israeli strikes on Iran and subsequent retaliatory actions, with the community actively debating whether crude oil prices will surge higher on potential Strait of Hormuz disruptions or if the rally will prove temporary despite a significant military buildup in the region.

SSgA Active Trust - State Street Energy Select Sector SPDR ETF

Energy Select Sector SPDR Fund

XLE is trending due to U.S. intervention in Venezuela and escalating geopolitical tensions in the Middle East, particularly around the Strait of Hormuz, which is fueling a significant "war risk premium" in oil prices and leading the community to anticipate massive upside for energy stocks.

MediWound Ltd. is a biopharmaceutical company, which engages in the development, manufacture, and commercialization of products to address needs in the fields of severe burns, chronic wounds, and other hard-to-heal wounds. Its product NexoBrid, is an orphan biologic for eschar removal in severe burns. The company was founded by Lior Rosenberg and Marian Gorecki in January 2000 and is headquartered in Yavne, Israel.

MediWound Ltd

MediWound is trending as investors eagerly anticipate a potential BARDA contract for its burn treatment NexoBrid, which recently showed strong efficacy in blast injuries, alongside promising advancements for its EscharEx chronic wound therapy. This momentum, including institutional interest and buyout speculation, is driving conversation despite polarized views on the stock's ability to break through current trading ranges.

Indonesia Energy Corp. Ltd. operates as an oil and gas, exploration, and production company. It engages in oil and gas assets portfolio with a mix between medium-sized producing blocks and exploration blocks with significant resources. Its portfolio includes Kruh, Citarum, and Rangkas Area. The company was founded by James J. Huang and Wirawan Jusuf in 2014 and is headquartered in Jakarta, Indonesia.

Indonesia Energy Corp Ltd

Indonesia Energy Corp Ltd (INDO) is trending as escalating Middle East geopolitical tensions, including concerns over oil supply chokepoints like the Strait of Hormuz, are fueling community anticipation of surging crude prices and a potential short squeeze for this low-float energy stock.

Fan Tokens allow fans across multiple sports verticals to exercise their share of influence within their favourite teams/leagues/clubs. Through Socios.com, fans are empowered to participate in certain club decisions, for example, choosing a goal celebration song in a football stadium, choosing which fighters should go head to head in MMA, and more. Thanks to Fan Tokens, holders receive access to once-in-a-lifetime experiences such as player meet and greets, training day events &amp; much much more.  The growing list of partnerships launching their Fan Tokens on the Socios.com platform includes some of the biggest sporting organizations in the world such as FC Barcelona, Inter Milan, AC Milan, Manchester City, UFC, ROUSH Fenway Racing, Aston Martin, just to name a few.

Italian National Football Team Fan Token

The iShares U.S. Aerospace & Defense ETF (ITA) is trending amidst heightened global geopolitical tensions, including escalating conflicts in the Middle East and South Asia, prompting community discussion on potential impacts for defense spending and "war stocks." While some anticipate continued strength, others note recent profit-taking and market rotation out of the sector after a significant rally.

Chevron Corp. engages in the provision of oil and gas energy solutions. It provides crude oil and natural gas, manufactures transportation fuels, lubricants, petrochemicals, and additives, and develops technologies that enhance business and the industry. It operates through the Upstream and Downstream segments. The Upstream segment consists of the exploration, development, and production of crude oil and natural gas, the liquefaction, transportation, and regasification associated with liquefied natural gas, the transporting of crude oil by major international oil export pipelines, the processing, transporting, storage, and marketing of natural gas, and a gas-to-liquids plant. The Downstream segment consists of the refining of crude oil into petroleum products, the marketing of crude oil and refined products, the transporting of crude oil and refined products by pipeline, marine vessel, motor equipment, and rail car, and the manufacturing and marketing of commodity petrochemicals and plastics for industrial uses and fuel & lubricant additives. The company was founded on September 10, 1879 and is headquartered in Houston, TX.

Chevron Corp.

Chevron is trending as intensifying geopolitical tensions in the Middle East, particularly regarding potential oil supply disruptions and the Strait of Hormuz, are driving crude prices higher. The community is actively discussing Chevron's strategic advantages, including expanded access to Venezuelan oil and new global exploration deals, positioning it for potential gains amid these market shifts.

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

BioNTech SE - ADR

BioNTech is trending amid enthusiasm for positive Phase 3 clinical trial results for its HER2-positive breast cancer drug and encouraging lung cancer therapy data, fueling community discussions about its oncology pipeline and strategic pivot, even as some debate recent analyst upgrades against news of a partner offloading its stake.

SSgA Active Trust - State Street SPDR Dow Jones Industrial Average ETF Trust

DIA is trending amidst escalating US-Iran geopolitical tensions, characterized by reports of military actions and leadership changes, coupled with market uncertainty following the Supreme Court's tariff ruling and subsequent threats of new tariffs from President Trump. The community is sharply divided between anticipating a potential market rally and fearing a significant downturn due to these events and broader economic concerns.

Listed Funds Trust - Roundhill Magnificent Seven ETF

Roundhill Magnificent Seven ETF

The Roundhill Magnificent Seven ETF ($MAGS) is a major talking point as its mega-cap tech holdings exhibit recent underperformance against the broader market, prompting community debate over a potential rotation into other sectors or the unwinding of an AI-driven valuation bubble.

Global X Funds - Global X Silver Miners ETF

The Global X Silver Miners ETF is actively discussed amid a tightening physical silver supply and surging industrial demand from AI and EVs, fueling a "silver squeeze" narrative. Despite current frustration over miners lagging the metal's price surge, the community widely anticipates a significant catch-up rally, viewing the sector as historically undervalued.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>CEO Brent Ness outlined a 2026 execution plan focused on reimbursement, evidence, and adoption.</li><li>Monetization is underway through UK coverage, cash-pay usage, and paid trials.</li><li>Scanner expansion is seen as a key lever to broaden market reach.</li></ul>Aclarion Inc.’s stock has plunged nearly 98% over the past year, putting the spotlight back on the artificial intelligence-driven medical imaging company almost four years after it went public. Despite the steep decline, Aclarion is now attempting to follow a path similar to HeartFlow,&nbsp;an AI medtech firm focused on cardiac imaging, that went public just months ago with significantly higher quarterly revenue and greater investor visibility.In an exclusive interview with Stocktwits, CEO Brent Ness said Aclarion is already generating revenue. In this interview, edited for clarity, Ness explained how the Broomfield, Colorado-based company is working to regain investor confidence after a prolonged period of decline.<h2 class="st-heading-2">HeartFlow's Playbook Offers Guidance For Aclarion</h2>Ness compared Aclarion’s strategy to that of advanced imaging companies such as HeartFlow, noting that the “raw material data” comes from imaging centers, is processed in the cloud, and is delivered to physicians in a clinically meaningful report.Under this structure, imaging centers generate raw data that is processed through Aclarion’s platform and translated into clinically meaningful reports for physicians. Ness said customer acquisition and technology development are expensive, but delivering a cloud-to-customer scan has a “nice margin profile.”He said investors should look at HeartFlow “as a proxy business” when thinking about Aclarion’s economic profile. HeartFlow’s platform uses AI to generate personalized three-dimensional models of the heart, helping make coronary artery disease more screenable, diagnosable and manageable.Aclarion went public in April 2022, while HeartFlow made its market debut in August 2025. Over the past six months, HTFL has shed about 1.3% to keep its market capitalization at $2.45 billion, while ACON has slumped by nearly 60%, with its valuation hovering just above $3 million.&nbsp;HeartFlow’s quarterly revenue has increased from $26.8 million in the first quarter of 2024 to $46.3 million in the third quarter of 2025, while adjusted losses narrowed slightly, from $15.6 million to $14.8 million over the same period.&nbsp;Aclarion had approximately $21 million in cash at the beginning of January, giving the company a funding runway through 2028.<img src="https://news.stocktwits-cdn.com/Heart_Flow_Revenue_and_EBITDA_jpg_728fe48fd3.webp" alt="HeartFlow_Revenue_and_EBITDA.jpg"><h2 class="st-heading-2">A Big Market With Room To Scale</h2>Ness said Aclarion’s opportunity spans a large patient population, noting that approximately 266 million people worldwide live with chronic low back pain. He said the company’s addressable market spans multiple layers of care, including spinal fusion surgeries, non-fusion procedures, and pain management, collectively increasing the potential number of scans over time.According to a MarketsandMarkets&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.marketsandmarkets.com/PressReleases/ai-in-medical-imaging.asp">report</a>, the global AI in medical imaging market is projected to reach $4.54 billion by 2029, up from $1.65 billion in 2024, reflecting a 22.4% compound annual growth rate. The report said growth is driven by the rising adoption of AI software that improves diagnostic accuracy, streamlines workflows, and helps providers manage increasing imaging volumes.On potential near-term catalysts, Ness said the company is focused on reimbursement progress and expanding access. “We’re currently in the market only with Siemens scanners. If you see Philips scanners, Canon scanners, GE scanners coming on board, then that will increase the penetrable market size significantly.”<h2 class="st-heading-2">Early Monetization Gains Ground</h2>Ness said Aclarion is generating revenue from multiple sources, including reimbursed Nociscan scans in the UK, cash-pay usage, and paid clinical trials that compensate the company for use of its technology.He said the UK, particularly London, has played a key role because insurance coverage reduces financial friction for physicians and patients, thereby supporting higher utilization and growth in scan volume.Ness said clinical trials are also generating revenue, with some studies paying Aclarion to use Nociscan to evaluate spine treatments and biologics. He said this allows evidence generation to function as an income stream rather than a pure cost center, helping offset operating expenses and reducing reliance on capital markets during key development milestones.<h2 class="st-heading-2">Aclarion Clarity Trial And Reimbursement Pathway</h2>Ness said Aclarion’s national randomized Clarity trial is central to its U.S. reimbursement strategy. The trial is designed to enroll up to 300 patients, with physicians blinded or unblinded to Nociscan results. It will measure outcomes at 3, 6, and 12 months post-surgery, with additional follow-up at 24 months.Since it is a post-market study and not an FDA approval trial, he said the study includes an early-stop design, meaning enrollment could be halted if outcome separation becomes statistically significant, potentially accelerating discussions with insurers.Ness said that a 2025 paper by an independent PhD healthcare economist found Nociscan reduced costs by about $1,700 per patient, strengthening the case for payer adoption. He added that nearly $2.2 billion is spent each year in the U.S. on fusion revision surgeries, and said reducing that figure is a significant opportunity for payers.<h2 class="st-heading-2">ACON vs HTFL: Which Stock Is Getting Higher Retail Interest?</h2>On Stocktwits, Aclarion’s retail sentiment was ‘bearish’ amid ‘extremely low’ message volume, a sharp shift from ‘extremely bullish’ sentiment a year ago. HeartFlow’s sentiment was also ‘bearish’ with ‘normal’ message volume, down from ‘neutral’ levels last year.<figure class="image"><img src="https://news.stocktwits-cdn.com/acon_ss_png_3176ea0056.webp" alt="acon ss.png" width="967" height="140"><figcaption>ACON sentiment and message volume as of February 4 | Source: Stocktwits</figcaption></figure><figure class="image"><img src="https://news.stocktwits-cdn.com/htfl_ss_png_d3f3abe807.webp" alt="htfl ss.png" width="966" height="141"><figcaption>HTFL sentiment and message volume as of February 4 | Source: Stocktwits</figcaption></figure>One user said they were accumulating Aclarion shares and watching closely for a pickup in trading volume, adding that “a fast double is very possible.”<stembedurl>https://stocktwits.com/KuruHabesha/message/643772716</stembedurl>Another Stocktwits user said HeartFlow’s momentum would likely persist only if the company continues to show consistency quarter to quarter, adding that operational execution needs to tighten meaningfully and that sustained improvement could help validate the long-term thesis.<stembedurl>https://stocktwits.com/MarketSignalMatrix/message/640221754</stembedurl>Up until the end of January, HTFL notched a more than 15% jump in watchers on Stocktwits over a three-month period, while ACON saw a merely 2.7% rise in followers, indicating stronger growth in retail investor interest for Heartflow. Message volume for HTFL doubled over the same period, while ACON witnessed a 25% drop.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Aclarion logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

EXCLUSIVE: Aclarion CEO Looks To Bigger AI MedTech’s Playbook To Reverse Fortunes 

CEO Brent Ness noted a broad global market, with approximately 266 million people affected by chronic low back pain.

Aclarion CEO Bets On Bigger AI MedTech’s Playbook To Revive Sagging Stock

Equity

<ul class="summary-bullets"><li>A Supreme Court ruling on tariffs and the U.S. jobs report were scheduled for Friday.</li><li>Housing, biotech and aviation stocks saw notable moves during regular and extended trading.</li><li>Markets tracked developments related to trade policy, mortgage bonds and economic data.</li></ul>U.S. stock futures were mixed late Thursday as investors positioned cautiously ahead of a key U.S. jobs report and weighed a series of policy signals out of Washington that could influence trade, rates, and housing markets.As of 9.05 P.M. ET, Nasdaq 100 futures were down 0.2%, while S&amp;P 500 futures&nbsp;were down by 0.1%. Dow futures were up 0.6%.On Stocktwits, retail sentiment toward the&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF Trust (SPY)</a> was ‘neutral’, while sentiment toward the&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust (QQQ)</a> was ‘bullish’ and sentiment toward the&nbsp;<a href="https://stocktwits.com/symbol/DIA">SPDR Dow Jones Industrial Average ETF Trust (DIA)</a> was ‘extremely bearish’, all amid ‘high’ message volume.<h2 class="st-heading-2">Market Drivers</h2>Markets reacted to two potential catalysts heading into Friday: a possible ruling from the U.S. Supreme Court on the legality of tariffs imposed under President Donald Trump and his latest comments on mortgage markets.In the prior session, the Dow Jones Industrial Average rose 0.6%, while the S&amp;P 500 climbed 0.01% and the Nasdaq Composite slid 0.4%.Trump said in a social media post on Thursday that he is instructing his representatives to&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/trump-instructs-to-buy-200-billion-dollars-in-mortgage-bonds/cmUbZfwR45k">buy $200 billion in mortgage bonds</a>, arguing that the move would help lower mortgage rates and monthly payments. He added that Fannie Mae and Freddie Mac have about $200 billion in cash, framing the directive as a way to make homeownership more affordable.The comments came a day after Trump said he would&nbsp;seek to ban large institutional investors from buying single-family homes, citing rising inflation and high housing costs as a growing barrier for younger Americans.<h2 class="st-heading-2">Peter Schiff Pushes Back On Mortgage Bond Buying</h2>Economist Peter Schiff&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/PeterSchiff/status/2009416426738626693">said on X</a> that lower home prices, rather than additional credit, were the only solution to the housing affordability crisis. He argued that directing more government-backed credit into the mortgage market would allow buyers to stretch further and overpay for homes, worsening the problem.Schiff also said&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/PeterSchiff/status/2009391071760142624">in a separate post</a> that if the $200 billion were sourced from government-sponsored entities, it could reduce availability for U.S. Treasuries. While such purchases might temporarily push mortgage rates lower, he warned they could also lead to higher Treasury yields and increased inflation pressures.<h2 class="st-heading-2">Trending Stocks To Watch</h2>Opendoor Technologies: Shares jumped more than 12% after hours after rising about 5% in regular trading, as comments on mortgage-related policy lifted housing-linked stocks.Rocket Companies: The stock gained 7% in extended trading after slipping 0.2% during the regular session, also moving on mortgage and rate-related news.Aclarion: Shares fell about 13% after hours after surging more than 42% in regular trading, following an&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/acon-stock-pops-pre-market-today-what-s-driving-the-move/cmUbeT3R4Pp">update on business progress</a>, rising demand for its Nociscan platform, and its financial position heading into 2026.flyExclusive: The stock more than doubled during regular trading, up over 130%, after the company announced an&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/flyx-stock-surges-130-percent-whats-the-spacex-connection/cmUbfvrR45T">authorized dealership agreement with Starlink</a> to install high-speed connectivity across its fleet.Oscar Health: Shares rose nearly 7% after hours after gaining about 3% in regular trading, as&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/oscar-health-stock-surges-over-after-hours-as-house-backs-obamacare-subsidies/cmUcxWmR45N">investors reacted to a House vote backing</a> ACA subsidy extensions, despite a disclosed insider share sale.Enliven Therapeutics: The stock added about 1% after hours after soaring roughly 50% during the session, following positive early data from its&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-did-elvn-stock-shoot-up-60-percent-today/cmUbQNvR45E">Phase 1b Enable trial</a> for ELVN-001 in chronic myeloid leukemia.<h2 class="st-heading-2">Broader Markets</h2>In broader markets, oil prices rebounded after two straight days of declines, settling at a two-week high. Brent crude rose $2.03, or 3.4%, to $61.99 a barrel, while U.S. West Texas Intermediate gained $1.77, or 3.2%, to $57.76.&nbsp;The yield on the benchmark 10-year U.S. Treasury was last around 4.18%. Asian equities were mixed, with shares opening higher in Japan and Australia, while South Korea lagged.Among the catalysts for the day are housing starts and building permits figures, updated University of Michigan consumer sentiment readings, and remarks from Minneapolis Fed President Neel Kashkari and Richmond Fed President Tom Barkin.For updates and corrections, email newsroom[at]stocktwits[dot]com.

People walk past the New York Stock Exchange (NYSE) on August 22, 2025, in New York City. (Photo by Spencer Platt/Getty Images)

S&P 500, Nasdaq Futures Waver Ahead Of Supreme Court Ruling On Trump Tariffs: Why OPEN, ACON, FLYX, OSCR Are Trending After-Hours

Attention also centered on Trump’s comments on proposed mortgage bond purchases.

Healthcare Stocks To Keep An Eye On - January 8th

UnitedHealth Group, Johnson & Johnson, Intuitive Surgical, Aclarion, and Hims & Hers Health are the five Healthcare stocks to watch today, according to MarketBeat's stock screener tool. As it...

<ul class="summary-bullets"><li>In 2025, Aclarion added nine imaging sites and more than 20 new physician users.</li><li>The company reported a 69% increase in annual scan volume, capped by triple-digit growth in the fourth quarter.</li><li>Looking to 2026, the company expects to speed up CLARITY trial enrollment, and roll out a new version of its software to improve workflow integration.&nbsp;</li></ul>Aclarion, Inc. (ACON) stock shot up over 45% on Thursday’s premarket after the company shared an overview of its latest business progress and financial performance as it heads into 2026 and continues to develop its Nociscan platform.The healthcare technology company focuses on helping physicians pinpoint the source of chronic lower back pain using biomarkers and advanced analytics embedded in its Nociscan platform.<h2 class="st-heading-2">Momentum Gained In 2025</h2>Demand for Nociscan continued to accelerate through 2025, with scan volumes rising sharply across the U.S., the U.K., and Europe as new imaging centers and physician users came onboard.In 2025, Aclarion added nine imaging sites and more than 20 new physician users. The company said these steps supported a 69% increase in annual scan volume, capped by triple-digit growth in the fourth quarter.On Stocktwits, retail sentiment around&nbsp;<a href="https://stocktwits.com/symbol/ACON">Aclarion stock</a> jumped to ‘extremely bullish’ from ‘bearish’ territory the previous day. Message volume shifted to ‘extremely high’ from ‘low’ levels in 24 hours.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_01_08_073305_png_e7268d46e3.webp" alt="ACON’s Sentiment Meter and Message Volume as of 07:30 a.m. ET on Jan. 8, 2026 | Source: Stocktwits" width="932" height="104"><figcaption>ACON’s Sentiment Meter and Message Volume as of 07:30 a.m. ET on Jan. 8, 2026 | Source: Stocktwits</figcaption></figure>Aclarion launched its CLARITY trial in 2025, activating seven sites to evaluate real-world performance. The company also published data indicating Nociscan could lower per-patient costs and improve surgical success rates.<h2 class="st-heading-2">Plans For 2026</h2>Looking to 2026, the company expects to speed up CLARITY trial enrollment, expand compatibility with additional MRI manufacturers, and roll out a new version of its software to improve workflow integration.&nbsp;<blockquote>“We are pleased with the progress Aclarion has made in strengthening our financial position, expanding clinical traction, and advancing Nociscan toward broader adoption.”- Brent Ness, CEO, Aclarion</blockquote>As of the end of 2025, Aclarion reported $12 million in cash and no outstanding debt. Based on current spending levels, the company said it has sufficient resources to operate into the first half of 2027.ACON stock has declined by over 99% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/exclusive-richtech-robotics-coo-bets-on-single-use-robots-as-dex-targets-real-world-labor-gaps/cmUb5USR4Pj">Exclusive: Richtech Robotics COO Bets On Single-Use Robots As Dex Targets Real-World Labor Gaps</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

 In this photo illustration, the Aclarion logo is seen displayed on a smartphone screen.

ACON Stock Pops 45% Pre-Market Today: What’s Driving The Move?

The company said demand for Nociscan continued to accelerate through 2025, with scan volumes rising sharply across the U.S., the U.K., and Europe as new imaging centers and physician users came onboard.

AMN Healthcare Services (AMN) Tops Q2 Earnings and Revenue Estimates

AMN Healthcare (AMN) delivered earnings and revenue surprises of +76.47% and +0.87%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Healthcare technology firm Aclarion Inc.'s (ACON) stock surged nearly 127% on Monday, marking its best single-day gain since going public in 2022.&nbsp;The surge followed news that Aclarion has entered into a commercial agreement with Scripps Health, bringing its Nociscan technology — a noninvasive tool that helps physicians personalize treatment for chronic lower back pain — to Scripps' network of doctors in San Diego, California.Aclarion says the deal will allow Scripps physicians to better differentiate between painful and non-painful lumbar discs using magnetic resonance spectroscopy and advanced signal processing.&nbsp;While the partnership's financial terms were not disclosed, the news generated widespread enthusiasm among retail traders, driving a dramatic surge in trading activity and online discussions.Investor chatter on Stocktwits turned sharply bullish in response to the announcement. The company's follower count on the platform jumped nearly 20%, while message volume surged by over 6,000% by the end of Monday's session.A Stocktwits poll found that 41% of more than 1,100 retail traders view the partnership as a "game-changer," while 32% describe it as "short-term hype, long-term unknown." The remaining see it as a "liquidity event" or too early to make a definitive judgment.Retail traders debated the deal's broader implications, with one suggesting that it could make Aclarion a potential acquisition target for major medical technology firms.&nbsp;One user speculated that a buyout by a company like Medtronic could send the stock significantly higher, while another dismissed concerns about potential dilution, predicting a run to $10–$20.<stembedurl>https://stocktwits.com/TraderMitsos/message/606583790</stembedurl><stembedurl>https://stocktwits.com/Hotoilguy/message/606598370</stembedurl>Aclarion, which has a market capitalization of just $7.7 million, remains an early-stage company that has yet to generate revenue.&nbsp;Short interest on the stock has jumped from 11.8% at the start of 2025 to 24.2% by the end of last week, according to Koyfin.Following Monday's rally, <a href="https://stocktwits.com/symbol/ACON">Aclarion shares</a> are now up over 5% year-to-date. According to Koyfin data, only two analysts currently cover Aclarion, with one rating it a 'Buy' and the other a 'Hold.'The stock was seeing heavy profit-taking in Monday's after-hours trading, falling over 14%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Is Aclarion's Tie-Up With Scripps Health A Lasting Catalyst? Most Retail Traders Think It's A 'Game-Changer'

The company's follower count on Stocktwits jumped nearly 20%, while message volume surged by over 6,000% by the end of Monday's session.

Aclarion Inc. shares surged 94% on Thursday afternoon in heavy trading after the healthcare technology company executed a 1-for-335 reverse stock split.&nbsp;The move reduced its outstanding common shares from approximately 169.4 million pre-split to around 500,000 post-split.The reverse split propelled Aclarion to the top of Stocktwits’ trending tickers, with its retail following jumping 59% from Wednesday’s close.&nbsp;Bullish traders speculated the stock could climb another 45% from current levels, while some anticipated a near-tripling.<stembedurl>https://stocktwits.com/GreenReaperx/message/602177528</stembedurl><stembedurl>https://stocktwits.com/SCNC/message/602177417</stembedurl>Aclarion specializes in Magnetic Resonance Spectroscopy (MRS) and augmented intelligence algorithms to help physicians pinpoint sources of chronic low back pain through its SaaS platform, Nociscan.&nbsp;Earlier this month, the stock received a boost after the company announced it had terminated an agreement with Ascendiant Capital for a $10 million at-the-market share offering.&nbsp;According to a regulatory filing, Aclarion raised about $300,000 in gross proceeds before canceling the deal, which was initiated in September 2024.Despite losing&nbsp;over 71% of its value over the past three months, Aclarion’s retail following on Stocktwits has surged 50%, with message volume soaring over 6,000%.Aclarion’s stock last had a short interest of 17.4%, according to Koyfin data.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Representative image of a stock chart | Image source: Maria Korneeva on Getty Images

Aclarion’s Retail Following Jumps 60% After Reverse Stock Split As Micro-Cap Health Tech Shares Nearly Double

Earlier this month, the stock received a boost after the company announced it had terminated an agreement with Ascendiant Capital for a $10 million at-the-market share offering.

Aclarion, Inc. is a healthcare technology company, which engages in the provision of Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. It utilizes Artificial Intelligence to assist in quality control processes that flag spectroscopy data indicative of a poor MRS study. It offers NOCISCAN Suite, a revolutionary software suite that works with existing high field Magnetic Resonance systems and Magnetic Resonance Spectroscopy pulse sequence packages using an optimized protocol to conduct MRS exams of lumbar discs. The company was founded by James C. Peacock, David S. Bradford, and Jeffrey Lotz in 2008 and is headquartered in Broomfield, CO.

Aclarion Inc

Day trading

Swing trading

Long-term investing

Sitting in cash

Markets have been volatile, with macro headlines and earnings driving sharp moves. How are you positioning right now?

Drop your approach below 👇

ACON
Aclarion Inc

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest ACON News

ACONAclarion Inc